Trials / Completed
CompletedNCT00535509
Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 285 (actual)
- Sponsor
- King Faisal Specialist Hospital & Research Center · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Phase II trial of Neoadjuvant \[FEC100\]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Cisplatin-Docetaxel ± Trastuzumab | Chemo \& RT |
| OTHER | Cisplatin-Docetaxel ± Trastuzumab | Chemo \& RT |
| DRUG | Cisplatin-Docetaxel ± Trastuzumab | Chemo \& RT |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2007-09-26
- Last updated
- 2015-12-17
Source: ClinicalTrials.gov record NCT00535509. Inclusion in this directory is not an endorsement.